Search Results | Clinical Cancer Research | American Association for Cancer Research

1-15 of 15

Sort by

Sort Order Select

Journal Articles

Phase II Clinical Trial of Everolimus in a Pan-Cancer Cohort of Patients with mTOR Pathway Alterations

Elio Adib, Katarzyna Klonowska, Krinio Giannikou, Khanh T. Do, Solida Pruitt-Thompson, Ketki Bhushan, Matthew I. Milstein, Jennifer Hedglin, Katherine E. Kargus, Lynette M. Sholl, Junko Tsuji, David M. Hyman, Anne Sisk, Geoffrey I. Shapiro, Hebert A. Vargas, James J. Harding, Martin H. Voss, Gopa Iyer, David J. Kwiatkowski

Clin Cancer Res (2021) 27 (14): 3845–3853.

DOI: https://doi.org/10.1158/1078-0432.CCR-20-4548

Published: 15 July 2021

View article

Includes: Supplementary data

Journal Articles

Overcoming MET-Dependent Resistance to Selective RET Inhibition in Patients with RET Fusion–Positive Lung Cancer by Combining Selpercatinib with Crizotinib

Clin Cancer Res (2021) 27 (1): 34–42.

DOI: https://doi.org/10.1158/1078-0432.CCR-20-2278

Published: 04 January 2021

View article

Includes: Supplementary data

Journal Articles

Impact of DNA Damage Response and Repair (DDR) Gene Mutations on Efficacy of PD-(L)1 Immune Checkpoint Inhibition in Non–Small Cell Lung Cancer

Biagio Ricciuti, Gonzalo Recondo, Liam F. Spurr, Yvonne Y. Li, Giuseppe Lamberti, Deepti Venkatraman, Renato Umeton, Andrew D. Cherniack, Mizuki Nishino, Lynette M. Sholl, Geoffrey I. Shapiro, Mark M. Awad, Michael L. Cheng

Clin Cancer Res (2020) 26 (15): 4135–4142.

DOI: https://doi.org/10.1158/1078-0432.CCR-19-3529

Published: 03 August 2020

View article

Includes: Supplementary data

Journal Articles

Identification of a RAS-activating TMEM87A–RASGRF1 Fusion in an Exceptional Responder to Sunitinib with Non–Small Cell Lung Cancer

Alissa J. Cooper, Yoshihisa Kobayashi, Dewey Kim, Sarah E. Clifford, Sasha Kravets, Suzanne E. Dahlberg, Emily S. Chambers, Jiaqi Li, Deepa Rangachari, Tom Nguyen, Daniel B. Costa, Michael S. Rabin, Nikhil Wagle, Lynette M. Sholl, Pasi A Jänne, Geoffrey R. Oxnard

Clin Cancer Res (2020) 26 (15): 4072–4079.

DOI: https://doi.org/10.1158/1078-0432.CCR-20-0397

Published: 03 August 2020

View article

Includes: Supplementary data

Journal Articles

Generation of Genetically Engineered Mouse Lung Organoid Models for Squamous Cell Lung Cancers Allows for the Study of Combinatorial Immunotherapy

Clin Cancer Res (2020) 26 (13): 3431–3442.

DOI: https://doi.org/10.1158/1078-0432.CCR-19-1627

Published: 01 July 2020

View article

Includes: Supplementary data

Journal Articles

Molecular Mechanisms of Acquired Resistance to MET Tyrosine Kinase Inhibitors in Patients with MET Exon 14–Mutant NSCLC

Clin Cancer Res (2020) 26 (11): 2615–2625.

DOI: https://doi.org/10.1158/1078-0432.CCR-19-3608

Published: 01 June 2020

View article

Includes: Supplementary data

Journal Articles

Amplification of Wild-type KRAS Imparts Resistance to Crizotinib in MET Exon 14 Mutant Non–Small Cell Lung Cancer

Clin Cancer Res (2018) 24 (23): 5963–5976.

DOI: https://doi.org/10.1158/1078-0432.CCR-18-0876

Published: 03 December 2018

View article

Includes: Supplementary data

Journal Articles

The Impact of Smoking and TP53 Mutations in Lung Adenocarcinoma Patients with Targetable Mutations—The Lung Cancer Mutation Consortium (LCMC2)

Clin Cancer Res (2018) 24 (5): 1038–1047.

DOI: https://doi.org/10.1158/1078-0432.CCR-17-2289

Published: 28 February 2018

View article

Includes: Supplementary data

Journal Articles

Identification of Existing Drugs That Effectively Target NTRK1 and ROS1 Rearrangements in Lung Cancer

Curtis R. Chong, Magda Bahcall, Marzia Capelletti, Takayuki Kosaka, Dalia Ercan, Taebo Sim, Lynette M. Sholl, Mizuki Nishino, Bruce E. Johnson, Nathanael S. Gray, Pasi A. Jänne

Clin Cancer Res (2017) 23 (1): 204–213.

DOI: https://doi.org/10.1158/1078-0432.CCR-15-1601

Published: 02 January 2017

View article

Includes: Supplementary data

Journal Articles

PD-1 Inhibitor–Related Pneumonitis in Advanced Cancer Patients: Radiographic Patterns and Clinical Course

Mizuki Nishino, Nikhil H. Ramaiya, Mark M. Awad, Lynette M. Sholl, Jennifer A. Maattala, Myriam Taibi, Hiroto Hatabu, Patrick A. Ott, Philippe F. Armand, F. Stephen Hodi

Clin Cancer Res (2016) 22 (24): 6051–6060.

DOI: https://doi.org/10.1158/1078-0432.CCR-16-1320

Published: 15 December 2016

View article

Journal Articles

Clinical and Molecular Characteristics of NF1-Mutant Lung Cancer

Amanda J. Redig, Marzia Capelletti, Suzanne E. Dahlberg, Lynette M. Sholl, Stacy Mach, Caitlin Fontes, Yunling Shi, Poornima Chalasani, Pasi A. Jänne

Clin Cancer Res (2016) 22 (13): 3148–3156.

DOI: https://doi.org/10.1158/1078-0432.CCR-15-2377

Published: 30 June 2016

View article

Includes: Supplementary data

Journal Articles

Immunohistochemical Loss of LKB1 Is a Biomarker for More Aggressive Biology in KRAS-Mutant Lung Adenocarcinoma

Antonio Calles, Lynette M. Sholl, Scott J. Rodig, Ashley K. Pelton, Jason L. Hornick, Mohit Butaney, Christine Lydon, Suzanne E. Dahlberg, Geoffrey R. Oxnard, David M. Jackman, Pasi A. Jänne

Clin Cancer Res (2015) 21 (12): 2851–2860.

DOI: https://doi.org/10.1158/1078-0432.CCR-14-3112

Published: 14 June 2015

View article

Includes: Supplementary data

Journal Articles

Clinical, Pathologic, and Biologic Features Associated with BRAF Mutations in Non–Small Cell Lung Cancer

Stephanie Cardarella, Atsuko Ogino, Mizuki Nishino, Mohit Butaney, Jeanne Shen, Christine Lydon, Beow Y. Yeap, Lynette M. Sholl, Bruce E. Johnson, Pasi A. Jänne

Clin Cancer Res (2013) 19 (16): 4532–4540.

DOI: https://doi.org/10.1158/1078-0432.CCR-13-0657

Published: 13 August 2013

View article

Includes: Supplementary data

Journal Articles

Clinicopathologic Features and Long-term Outcomes of NUT Midline Carcinoma

Daniel E. Bauer, Chelsey M. Mitchell, Kelly M. Strait, Christopher S. Lathan, Edward B. Stelow, Sonja C. Lüer, Somala Muhammed, Andrew G. Evans, Lynette M. Sholl, Juan Rosai, Eugenia Giraldi, Richard P. Oakley, Carlos Rodriguez-Galindo, Wendy B. London, Stephen E. Sallan, James E. Bradner, Christopher A. French

Clin Cancer Res (2012) 18 (20): 5773–5779.

DOI: https://doi.org/10.1158/1078-0432.CCR-12-1153

Published: 14 October 2012

View article

Includes: Supplementary data

Journal Articles

Mutation-Specific Antibodies for the Detection of EGFR Mutations in Non–Small-Cell Lung Cancer

Clin Cancer Res (2009) 15 (9): 3023–3028.

DOI: https://doi.org/10.1158/1078-0432.CCR-08-2739

Published: 30 April 2009

View article

Includes: Supplementary data

NARROW

Phase II Clinical Trial of Everolimus in a Pan-Cancer Cohort of Patients with mTOR Pathway Alterations

Overcoming MET-Dependent Resistance to Selective RET Inhibition in Patients with RET Fusion–Positive Lung Cancer by Combining Selpercatinib with Crizotinib

Impact of DNA Damage Response and Repair (DDR) Gene Mutations on Efficacy of PD-(L)1 Immune Checkpoint Inhibition in Non–Small Cell Lung Cancer

Identification of a RAS-activating TMEM87A–RASGRF1 Fusion in an Exceptional Responder to Sunitinib with Non–Small Cell Lung Cancer

Generation of Genetically Engineered Mouse Lung Organoid Models for Squamous Cell Lung Cancers Allows for the Study of Combinatorial Immunotherapy

Molecular Mechanisms of Acquired Resistance to MET Tyrosine Kinase Inhibitors in Patients with MET Exon 14–Mutant NSCLC

Amplification of Wild-type KRAS Imparts Resistance to Crizotinib in MET Exon 14 Mutant Non–Small Cell Lung Cancer

The Impact of Smoking and TP53 Mutations in Lung Adenocarcinoma Patients with Targetable Mutations—The Lung Cancer Mutation Consortium (LCMC2)

Identification of Existing Drugs That Effectively Target NTRK1 and ROS1 Rearrangements in Lung Cancer

PD-1 Inhibitor–Related Pneumonitis in Advanced Cancer Patients: Radiographic Patterns and Clinical Course

Clinical and Molecular Characteristics of NF1-Mutant Lung Cancer

Immunohistochemical Loss of LKB1 Is a Biomarker for More Aggressive Biology in KRAS-Mutant Lung Adenocarcinoma

Clinical, Pathologic, and Biologic Features Associated with BRAF Mutations in Non–Small Cell Lung Cancer

Clinicopathologic Features and Long-term Outcomes of NUT Midline Carcinoma

Mutation-Specific Antibodies for the Detection of EGFR Mutations in Non–Small-Cell Lung Cancer

Email alerts

AACR Journals

Email alerts

AACR Journals

This Feature Is Available To Subscribers Only